[go: up one dir, main page]

CL2019002218A1 - Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. - Google Patents

Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Info

Publication number
CL2019002218A1
CL2019002218A1 CL2019002218A CL2019002218A CL2019002218A1 CL 2019002218 A1 CL2019002218 A1 CL 2019002218A1 CL 2019002218 A CL2019002218 A CL 2019002218A CL 2019002218 A CL2019002218 A CL 2019002218A CL 2019002218 A1 CL2019002218 A1 CL 2019002218A1
Authority
CL
Chile
Prior art keywords
treat
risk
reduce
cardiovascular disease
methods
Prior art date
Application number
CL2019002218A
Other languages
English (en)
Inventor
Narendra Lalwani
Diane Macdougall
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CL2019002218A1 publication Critical patent/CL2019002218A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA TRATAR O REDUCIR EL RIESGO DE ENFERMEDAD CARDIOVASCULAR QUE COMPRENDE ADMINISTRAR ETC-1002, EZETIMIBE Y UNA ESTATINA; FORMULACIÓN FARMACÉUTICA QUE COMPRENDE A ETC-1002, EZETIMIBE, UNA ESTATINA Y EXCIPIENTES; Y KIT QUE COMPRENDE A LA COMPOSICIÓN.
CL2019002218A 2017-02-08 2019-08-06 Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. CL2019002218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762456571P 2017-02-08 2017-02-08

Publications (1)

Publication Number Publication Date
CL2019002218A1 true CL2019002218A1 (es) 2020-02-21

Family

ID=63107115

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002218A CL2019002218A1 (es) 2017-02-08 2019-08-06 Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2021002447A CL2021002447A1 (es) 2017-02-08 2021-09-21 (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021002447A CL2021002447A1 (es) 2017-02-08 2021-09-21 (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Country Status (9)

Country Link
US (1) US20210361618A1 (es)
EP (2) EP3579827A4 (es)
JP (2) JP2020506241A (es)
CN (1) CN110536684A (es)
BR (1) BR112019016307A2 (es)
CL (2) CL2019002218A1 (es)
IL (1) IL268502A (es)
MX (1) MX2019009418A (es)
WO (1) WO2018148417A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
BR112019016307A2 (pt) 2017-02-08 2020-03-31 Esperion Therapeutics, Inc. Formulações de combinação de tripleto e métodos para tratar ou reduzir o risco de doença cardiovascular
CA3110346A1 (en) * 2018-08-24 2020-02-27 Esperion Therapeutics, Inc. Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
PH12021552553A1 (en) 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
BR112021025928A2 (pt) 2019-06-21 2022-05-10 Esperion Therapeutics Inc Métodos de preparação de ácido bempedoico e composições do mesmo
CN113133997B (zh) * 2020-01-20 2024-02-09 深圳市长卿医学研究院 一种含小檗碱的药物组合物及其用途
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109170A2 (en) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Combination therapy for treatment of cardiovascular diseases and related conditions
CA2861643C (en) * 2012-01-06 2020-10-06 Charles L. Bisgaier Methods of reducing risk of cardiovascular disease
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
GB201318793D0 (en) * 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
CN107530307A (zh) * 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
BR112019016307A2 (pt) 2017-02-08 2020-03-31 Esperion Therapeutics, Inc. Formulações de combinação de tripleto e métodos para tratar ou reduzir o risco de doença cardiovascular

Also Published As

Publication number Publication date
JP7716437B2 (ja) 2025-07-31
JP2020506241A (ja) 2020-02-27
EP4461295A3 (en) 2025-01-15
MX2019009418A (es) 2019-10-02
IL268502A (en) 2019-09-26
US20210361618A1 (en) 2021-11-25
CL2021002447A1 (es) 2022-04-22
BR112019016307A2 (pt) 2020-03-31
WO2018148417A1 (en) 2018-08-16
CN110536684A (zh) 2019-12-03
EP4461295A2 (en) 2024-11-13
EP3579827A1 (en) 2019-12-18
JP2023040237A (ja) 2023-03-22
EP3579827A4 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX387322B (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
CL2020000586A1 (es) Moduladores de la expresión de enac.
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.